→
Investors should consider the balance of Amgen's growth metrics against potential regulatory and financial risks.
Amgen Inc has a market capitalization of $213.08B and a current stock price of $393.13, reflecting a 4.55% increase from the previous close of $376.01. The company exhibits an impressive EPS growth of 88.23% year-over-year and a revenue growth of 9.95% year-over-year. Its P/E ratio stands at 27.63, while the dividend yield is 2.40%. The stock has traded within a 52-week range of $269.75 to $397.74.
Some investors cite Amgen's impressive EPS growth of 88.23% year-over-year as a strong indicator of its operational efficiency and potential for future profitability. Additionally, the company's revenue growth of 9.95% year-over-year suggests resilience in its core business amidst market fluctuations.
Conversely, concerns have been raised regarding Amgen's high debt-to-equity ratio of 5.78, which may pose risks during economic downturns. Furthermore, recent headlines indicate potential regulatory challenges, such as the Colorado Enbrel price cap setback, which could impact profitability.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start. Pro unlocks the full terminal at $20/mo.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Amgen Inc has a market capitalization of $213.08B and a current stock price of $393.13, reflecting a 4.55% increase from the previous close of $376.01. The company exhibits an impressive EPS growth of 88.23% year-over-year and a revenue growth of 9.95% year-over-year. Its P/E ratio stands at 27.63, while the dividend yield is 2.40%. The stock has traded within a 52-week range of $269.75 to $397.74.
Conversely, concerns have been raised regarding Amgen's high debt-to-equity ratio of 5.78, which may pose risks during economic downturns. Furthermore, recent headlines indicate potential regulatory challenges, such as the Colorado Enbrel price cap setback, which could impact profitability.
Some investors cite Amgen's impressive EPS growth of 88.23% year-over-year as a strong indicator of its operational efficiency and potential for future profitability. Additionally, the company's revenue growth of 9.95% year-over-year suggests resilience in its core business amidst market fluctuations.
Some investors cite Amgen's impressive EPS growth of 88.23% year-over-year as a strong indicator of its operational efficiency and potential for future profitability. Additionally, the company's revenue growth of 9.95% year-over-year suggests resilience in its core business amidst market fluctuations. Conversely, concerns have been raised regarding Amgen's high debt-to-equity ratio of 5.78, which may pose risks during economic downturns. Furthermore, recent headlines indicate potential regulatory challenges, such as the Colorado Enbrel price cap setback, which could impact profitability.
Amgen Inc has a market capitalization of $213.08B and a current stock price of $393.13, reflecting a 4.55% increase from the previous close of $376.01. The company exhibits an impressive EPS growth of 88.23% year-over-year and a revenue growth of 9.95% year-over-year. Its P/E ratio stands at 27.63, while the dividend yield is 2.40%. The stock has traded within a 52-week range of $269.75 to $397.74.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for AMGN at helmterminal.dev/analyze/AMGN, updated continuously during US market hours. No signup required.